Kawakami Y, Nishimura M I, Restifo N P, Topalian S L, O'Neil B H, Shilyansky J, Yannelli J R, Rosenberg S A
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):88-93. doi: 10.1097/00002371-199308000-00002.
The adoptive transfer of tumor-infiltrating lymphocytes (TILs) with interleukin-2 (IL-2) has antitumor activity in some patients with metastatic melanoma. We have analyzed molecular mechanisms of TIL recognition of human melanoma. Some cultured TILs specifically lysed autologous and some allogeneic melanomas sharing a variety of class I major histocompatibility complex (MHC) molecules. HLA-A2-restricted melanoma-specific TILs lysed many HLA-A2+ melanoma cell lines from different patients but failed to lyse HLA-A2- melanoma and HLA-A2+ nonmelanoma cell lines. However, these TILs were capable of lysing many naturally HLA-A2- melanomas after introduction of the HLA-A2.1 gene by vaccinia virus. These results indicate that shared melanoma antigens (Ag) are expressed in melanomas regardless of their human leukocyte antigen types. In order to identify these shared melanoma Ags, we have tested some known proteins expressed in melanoma. Expression of tyrosinase or HMB45 Ag correlated with lysis of TILs. We are also attempting to isolate antigenic peptides by high performance liquid chromatography separation and genes encoding melanoma Ag by cDNA expression cloning. The T-cell component of the antimelanoma response was also analyzed by determining the genetic structure of the T-cell receptor (TCR) used by melanoma TILs. However, we did not observe common TCR variable region usage by different melanoma TILs. We could establish melanoma cell clones and lines resistant to TIL lysis due to the absence of or defects in the expression of Ag, MHC, or beta 2-microglobulin molecules. These data indicate multiple mechanisms for melanoma escape from T-cell immunosurveillance.(ABSTRACT TRUNCATED AT 250 WORDS)
肿瘤浸润淋巴细胞(TILs)与白细胞介素-2(IL-2)的过继性转移在一些转移性黑色素瘤患者中具有抗肿瘤活性。我们分析了TILs识别人类黑色素瘤的分子机制。一些培养的TILs特异性裂解自体和一些共享多种I类主要组织相容性复合体(MHC)分子的同种异体黑色素瘤。HLA-A2限制性黑色素瘤特异性TILs裂解了来自不同患者的许多HLA-A2 +黑色素瘤细胞系,但未能裂解HLA-A2 -黑色素瘤和HLA-A2 +非黑色素瘤细胞系。然而,在通过痘苗病毒导入HLA-A2.1基因后,这些TILs能够裂解许多天然的HLA-A2 -黑色素瘤。这些结果表明,共享的黑色素瘤抗原(Ag)在黑色素瘤中表达,而与它们的人类白细胞抗原类型无关。为了鉴定这些共享的黑色素瘤Ag,我们测试了黑色素瘤中表达的一些已知蛋白质。酪氨酸酶或HMB45 Ag的表达与TILs的裂解相关。我们还试图通过高效液相色谱分离来分离抗原肽,并通过cDNA表达克隆来分离编码黑色素瘤Ag的基因。通过确定黑色素瘤TILs使用的确T细胞受体(TCR)的基因结构,也分析了抗黑色素瘤反应的T细胞成分。然而,我们没有观察到不同黑色素瘤TILs使用共同的TCR可变区。由于Ag、MHC或β2-微球蛋白分子表达缺失或缺陷,我们可以建立对TIL裂解具有抗性的黑色素瘤细胞克隆和细胞系。这些数据表明黑色素瘤逃避T细胞免疫监视的多种机制。(摘要截短于250字)